TSI launched its branded Promilin ingredient in October 2002, and according to marketing manager Liz Smith, it has "a few licensees" at the moment. She added that the granting of the patent will help with positioning.
Extracted from Trigonella foenum-graecum, it is a complex of bioactive amino acids, including the derivative 4-hydroxyisoleucine (4-OH-Ile).
The patent for which TSI has applied covers the use of Promilin in supporting metabolism and transporting glucose and carbohydrates into skeletal muscle cells, and in performing weight management.
A number of studies have been carried out into the effects of Promilin, including one that was published in the peer reviewed journal Amino Acids: The Forum for Amino Acid and Protein Research in October 2004, which showed its ability to increase muscle glycogen resynthesis after exercising.
"TSI is committed to developing novel nutraceutical ingredients that progress our customers' future," said TSI president Larry Kolb. "TSI considers its patent portfolio to be a valuable asset of the company and is therefore committed to protecting and preserving those rights against any potential infringers."
Smith told NutrIngredients-USA.com that some of TSI's competitors are currently making claims that would infringe on the patent. If it is indeed granted as expected, the company plans to take legal action against them.